Furthermore, CheckMate 214, another phase III clinical trial, reported no benefits in survival across PD-L1 levels under nivolumab–ipilimumab combination therapy for renal cell carcinoma [32]. Here, CD274 is linked to hereditary clear cell renal cell carcinoma.